Is Src a Viable Target for Treating Solid Tumours?

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|10|7|683-694

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.10, Iss.7, 2010-11, pp. : 683-694

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Amifostine worth extra cost in treating solid tumours

By  

Inpharma, Vol. 1, Iss. 1281, 2001-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Amifostine worth extra cost in treating solid tumours

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 306, 2001-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Src as a Therapeutic Target in Breast Cancer

By  

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 8, Iss. 4, 2008-12 ,pp. : 273-278

Bentham Science Publishers

Access to resources Recommend Favorite

Monoclonal Antibodies in Solid Tumours

By  

Current Clinical Pharmacology, Vol. 5, Iss. 3, 2010-08 ,pp. : 160-165

Bentham Science Publishers

Access to resources Recommend Favorite

Cyclodextrins and Oligonucleotide Delivery to Solid Tumours

By Dass Crispin R.  

Journal of Drug Targeting, Vol. 12, Iss. 1, 2004-01 ,pp. : 1-9

Informa Healthcare

Access to resources Recommend Favorite